Profile data is unavailable for this security.
About the company
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
- Revenue in EUR (TTM)6.85bn
- Net income in EUR1.33bn
- Incorporated2011
- Employees9.38k
- LocationUcb SAAllee de la Recherche, 60ANDERLECHT 1070BelgiumBEL
- Phone+32 25599999
- Fax+32 25599900
- Websitehttps://www.ucb.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 5.28bn | 976.07m | 38.27bn | 43.00k | 39.24 | -- | 30.69 | 7.24 | 43.70 | 45.45 | 236.59 | -- | -- | -- | -- | 13,211,420.00 | -- | 9.09 | -- | 12.38 | 79.97 | 73.38 | 18.62 | 16.07 | -- | -- | -- | 39.34 | 8.42 | 9.87 | 14.12 | 23.76 | 6.66 | 31.95 |
| Haleon PLC | -114.77bn | -114.77bn | 41.56bn | 24.00k | -- | 2.29 | -- | -- | -- | -- | -- | 1.77 | -- | -- | -- | -- | -- | 3.67 | -- | 4.23 | -- | 62.28 | -- | 11.97 | 0.6327 | -- | 0.3464 | 218.58 | -0.6105 | 5.78 | 37.46 | 17.10 | 5.53 | -- |
| CSL Ltd | 13.04bn | 2.52bn | 44.10bn | 32.07k | 17.56 | 2.72 | 12.67 | 3.38 | 8.67 | 8.67 | 44.90 | 56.04 | 0.4019 | 1.20 | 5.16 | 680,888.80 | 8.10 | 8.58 | 9.87 | 10.61 | 51.93 | 52.91 | 20.16 | 19.71 | 1.12 | 10.01 | 0.3494 | 47.42 | 5.12 | 11.20 | 13.63 | 7.38 | -6.11 | 7.95 |
| Bayer AG | 45.87bn | -198.00m | 44.89bn | 88.50k | -- | 1.52 | 13.20 | 0.9787 | -0.2015 | -0.2015 | 46.69 | 30.11 | 0.4344 | 1.58 | 4.52 | 494,165.80 | -0.1639 | -2.66 | -0.2205 | -3.61 | 56.35 | 57.98 | -0.3772 | -6.88 | 0.7096 | 2.33 | 0.5717 | -- | -2.16 | 1.37 | 13.23 | -- | 0.9479 | -47.66 |
| Jiangsu Hengrui Pharmaceuticals Co Ltd | 3.78bn | 911.64m | 45.74bn | 20.24k | 50.12 | 6.55 | -- | 12.09 | 1.17 | 1.17 | 4.84 | 8.97 | 0.5312 | 1.71 | 5.75 | 1,530,951.00 | 12.82 | 12.67 | 14.40 | 14.00 | 85.49 | 85.64 | 24.14 | 20.06 | 6.20 | -- | 0.0014 | 23.84 | 22.63 | 3.74 | 47.28 | 3.53 | 28.53 | 4.60 |
| Zoetis Inc | 7.98bn | 2.25bn | 46.64bn | 13.80k | 20.86 | -- | 18.04 | 5.85 | 6.02 | 6.02 | 21.33 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 71.87 | 70.67 | 28.23 | 27.03 | -- | 19.35 | -- | -- | 2.28 | 7.24 | 7.52 | 10.29 | -- | 20.11 |
| Takeda Pharmaceutical Co Ltd | 24.62bn | 622.81m | 49.22bn | 47.46k | 77.62 | 1.16 | 10.37 | 2.00 | 72.26 | 72.26 | 2,834.46 | 4,838.54 | 0.2926 | 1.17 | 6.17 | 94,080,250.00 | 0.7418 | 1.71 | 0.8772 | 2.04 | 65.33 | 67.66 | 2.54 | 5.99 | 0.6548 | 3.49 | 0.3884 | 123.75 | 7.45 | 6.84 | -25.08 | 19.53 | 9.82 | 1.72 |
| UCB SA | 6.85bn | 1.33bn | 53.24bn | 9.38k | 39.89 | 5.37 | 27.84 | 7.77 | 6.86 | 6.86 | 35.27 | 50.96 | 0.4174 | 1.46 | 4.26 | 730,219.70 | 8.12 | 4.98 | 10.21 | 6.20 | 73.38 | 71.71 | 19.45 | 13.00 | 1.01 | 11.23 | 0.2291 | 34.22 | 17.14 | 4.60 | 210.50 | 6.16 | 1.84 | 2.31 |
| Merck KGaA | 21.27bn | 2.96bn | 54.52bn | 62.35k | 18.46 | 1.88 | 11.20 | 2.56 | 6.79 | 6.79 | 48.92 | 66.55 | 0.4209 | 1.97 | 5.04 | 340,025.90 | 5.85 | 6.04 | 7.23 | 7.70 | 58.69 | 61.15 | 13.91 | 13.80 | 0.9686 | 18.28 | 0.2943 | 9.11 | 0.7765 | 5.55 | -1.66 | 16.54 | 16.42 | 11.10 |
| Regeneron Pharmaceuticals Inc | 12.08bn | 3.83bn | 69.79bn | 15.41k | 18.67 | 2.65 | 16.27 | 5.78 | 41.96 | 41.55 | 131.98 | 295.71 | 0.3663 | 0.6934 | 2.40 | 930,752.80 | 11.62 | 16.41 | 13.00 | 18.57 | 86.56 | 87.14 | 31.72 | 36.23 | 3.56 | -- | 0.0797 | 1.50 | 0.9921 | 11.04 | 3.10 | 5.31 | 14.58 | -- |
Data as of Feb 13 2026. Currency figures normalised to Ucb SA's reporting currency: Euro EUR
24.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 08 Jan 2026 | 14.31m | 7.36% |
| Wellington Management Co. LLPas of 14 May 2024 | 12.75m | 6.56% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 4.71m | 2.42% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 3.16m | 1.62% |
| BlackRock Investment Management (UK) Ltd.as of 06 Feb 2026 | 2.92m | 1.50% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 2.46m | 1.27% |
| Wellington Management International Ltd.as of 14 May 2024 | 1.80m | 0.93% |
| ELEVA Capital SASas of 30 Jun 2025 | 1.75m | 0.90% |
| Amundi Asset Management SASU (Investment Management)as of 30 Jan 2026 | 1.50m | 0.77% |
| Geode Capital Management LLCas of 05 Feb 2026 | 1.49m | 0.77% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
